A retrospective observational study of early experiences of vedolizumab treatment for inflammatory bowel disease in the UK: The REVIVE study

Results from clinical trials show that vedolizumab is an efficacious treatment for inflammatory bowel disease, namely Crohn's disease (CD) and ulcerative colitis (UC). However, there is limited evidence from real-world clinical practice, especially on early clinical experiences in the UK. To de...

Descripción completa

Detalles Bibliográficos
Autores principales: Cummings, Fraser, Gaya, Daniel R., Levison, Scott, Subramanian, Sreedhar, Owen, Glynn, Rathmell, Anna, Glen, Fiona, Demuth, Dirk, Meadowcroft, Simon, Irving, Peter M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
4500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831399/
https://www.ncbi.nlm.nih.gov/pubmed/30817598
http://dx.doi.org/10.1097/MD.0000000000014681

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831399/
https://www.ncbi.nlm.nih.gov/pubmed/30817598
http://dx.doi.org/10.1097/MD.0000000000014681

Ejemplares similares